We were over on QCOR together, a few months ago... BTW, that play is about to soar.
Anyway, if you are in MACK, I'd like to get your take on it. I've been doing as much research as is available out there but it's not much.
Any thoughts? or is this a spec play for you?
I am still in QCOR...I have a long term hold position and trading shares that I have been having fun with during this recent momentum leading up to earnings. I still peruse the QCOR message board and enjoy the camaraderie of the board in providing good research and opinions. Thanks for the input. I have to admit, I was in disbelief that Nomad is now in the bull camp. Is this legitimate?....I can't seem to trust it. LOL
Anyway, I am in MACK for a spec play as of 2/5/2012 when there was 2.15million shares accumulated at the close. I thought that this would increase momentum to retrace back to the 9/24 price before the bear raid, but not yet. Since then I researched that smart money has been accumulating, there are multiple drugs in the pipeline with catalysts this year. Therefore, I keep a small position and watch for when the momentum kicks in and then I will increase my position. I have not yet done an indepth research of Mack's drug offerings, but I like that their drugs are in advanced stages in their studies. I will ramp up my interest when an upward trend begins. 23% retracement is at $7.11....so when it crosses 7, I will be VERY interested.
Good to know.
Yes Nomad legitimately changed to long. Amazing, or timing... He is a mid-term trader (aren't we all to some degree). Once QCOR gets toppy, I'm sure he'll go short. Something to keep in mind is that he trades options, so he is really just looking for the PPS to move one way or the other to cover his bet.
I think I came to the same conclusion as you with MACK. Might be a real smart spec play, so I am getting a small position built. I think I've read everything available anywhere on the drugs in the pipeline now.
You peaked my interest too. I have done a good bit of research and I have been following paper trails for a few things. Very interesting company and a interesting philosophy on how to find drugs. One question, does anyone have access to the Phase 2 data ( For MM 398 I believe). All I can find is that it met its efficacy end points, but can't find any information on the trial.
I typical invest in stocks that have average volume of over 500k. This one is close, but today's volume was merely 175k. That's like really low. Liquidity may become an issue if you accumulate. Stock looks like it may turn here to upside.
Sentiment: Strong Buy
Hi Mike, Here's some research on Mack from a website I use.
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines consisting of novel therapeutics paired with companion diagnostics.
The company’s initial focus is in the field of oncology. It has five programs in clinical development. In its advanced program, the company is in the process of conducting a pivotal Phase 3 clinical trial. Its advanced product candidates are MM-398, MM-121, MM-111, MM-302 and MM-151.
MM-398 is a stable nanotherapeutic encapsulation, or enclosed sphere carrying an active drug, of the marketed chemotherapy drug irinotecan. The company is in the process of conducting a pivotal Phase 3 clinical trial of MM-398 for the treatment of patients with metastatic pancreatic cancer who have previously failed treatment with the chemotherapy drug gemcitabine. In July 2011, the FDA granted MM-398 orphan drug designation for the treatment of pancreatic cancer. In September 2011, the European Medicines Agency (EMA) granted MM-398 orphan medicinal product designation for the treatment of pancreatic cancer. MM-398 has potential uses in other indications, including colorectal cancer, lung cancer and glioma.
MM-121 is a fully human monoclonal antibody that targets ErbB3, a cell surface receptor, or protein attached to the cell membrane that mediates communication inside and outside the cell, implicated in cancer. A monoclonal antibody is a type of protein produced by cells of the immune system that binds to just one epitope, or chemical structure, on a protein or other structure. MM-121 is designed to inhibit cancer growth directly, restore sensitivity to drugs to which a tumor has become resistant and delay the development of resistance by a tumor to other agents. In collaboration with Sanofi, the company is in the process of conducting a clinical program to test MM-121 in combination with both chemotherapies and other targeted agents across solid tumor patient populations, including patients with lung, breast and ovarian cancers.
MM-111 is a bispecific antibody designed to target cancer cells that are characterized by overexpression of the ErbB2 cell receptor, also referred to as HER2. MM-111 is designed to address the signaling from this complex of molecules. MM-111 is potentially applicable across a range of solid tumors. The company is in the process of conducting multiple Phase 1 clinical trials of MM-111 in monotherapy and combination therapy settings.
MM-302 is a nanotherapeutic encapsulation of doxorubicin with attached antibodies that target the ErbB2 (HER2) receptor. The company designed MM-302 to bind to cancer cells that overexpress ErbB2 (HER2) and thereby release doxorubicin at the site of the tumor. The company is in the process of conducting a Phase 1 clinical trial of MM-302 in patients with advanced ErbB2 (HER2) positive breast cancer.
MM-151 is an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor, or EGFR. EGFR is also known as ErbB1. An oligoclonal therapeutic is a mixture of two or more distinct monoclonal antibodies. EGFR (ErbB1) has been recognized as an important drug target in several malignancies, including lung, breast, colon, pancreatic and head and neck cancers. The company is in the process of conducting a Phase 1 clinical trial of MM-151 in patients with solid tumors.
Preclinical product candidates
The company is in the process of developing preclinical product candidates for a range of solid tumor indications. Its advanced preclinical candidates are MM-141, MM-310 and MM-131.
MM-141 is a bispecific antibody designed to inhibit signaling mediated through the insulin growth factor 1 receptor (IGF-1R), by targeting IGF-1R and ErbB3.
MM-310 is a targeted nanotherapeutic.
MM-131 is a multispecific antibody.
MM-141 and MM-131 are the first candidates in the company’s pipeline to target multiple growth factors that are co-utilized for growth by a cancer cell.
Collaboration and License Agreements
Sanofi: In 2009, the company entered into a license and collaboration agreement with Sanofi for the development and commercialization of MM-121. Under the agreement, the company granted Sanofi a worldwide, royalty-bearing right and license, with the right to grant sublicenses, under its patent rights and know-how to develop and commercialize the monoclonal antibody MM-121 and an MM-121 companion diagnostic.
PharmaEngine, Inc. (PharmaEngine): In May 2011, the company entered into an assignment, sublicense and collaboration agreement with PharmaEngine. Under the agreement, PharmaEngine assigned to the company its rights and obligations under a 2005 agreement with Hermes BioSciences, Inc., or Hermes, to develop and commercialize MM-398 in Europe and certain countries in Asia. PharmaEngine also granted to the company an exclusive right and license, with the right to sublicense, under PharmaEngine technology and rights to develop and commercialize MM-398 worldwide outside of Taiwan.
Dyax Corp. (Dyax): In 2007, the company entered into an amended and restated collaboration agreement with Dyax. Under this collaboration agreement, Dyax uses its proprietary phage display technology to identify antibodies that bind to targets of interest to the company as therapeutics or diagnostics. Further, Dyax has granted to the company a worldwide, non-exclusive, royalty free right to use and make any and all of the antibodies identified by Dyax for certain research purposes.
Adimab LLC (Adimab): In 2009, the company entered into a collaboration agreement with Adimab, to allow the company to evaluate the utility of using antibodies identified during the collaboration as therapeutics or diagnostics. Under the agreement, Adimab granted to the company a worldwide, non-exclusive, royalty free right to use materials provided by Adimab to perform non-clinical research during the evaluation term.
University of California: In 2005, the company entered into a license agreement with The Regents of the University of California (Regents). Under the agreement, the Regents granted to the company a royalty-bearing right and license in the United States and other countries where the Regents have the right to grant the license under certain patent rights and rights in biological materials to develop and commercialize products for therapeutic or diagnostic use in humans that are covered by the licensed patents.
U.S. Public Health Service: In 2008, the company entered into a commercial license with the U.S. Public Health Service, a division of the U.S. Department of Health and Human Services, for non-exclusive rights in the United States to patents related to ErbB3 and ErbB3 antibodies associated with MM-121 and MM-111.
Selexis SA (Selexis): In June 2008, the company entered into a commercial license with Selexis SA for non-exclusive rights to technology for use in the manufacture of certain biologic products, including each of its five most advanced product candidates, other than MM-398.
As of February 29, 2012, the company owned 17 issued U.S. patents, 2 issued patents in Europe and 12 issued patents in other jurisdictions, as well as 28 pending U.S. provisional and non-provisional patent applications and 160 pending foreign patent applications in Europe and 42 other jurisdictions. As of February 29, 2012, the company also co-owned 11 pending U.S. provisional patent applications with Sanofi, as well as one U.S. non-provisional and one PCT application with Silver Creek Pharmaceuticals, Inc. As of February 29, 2012, the company had licenses to 37 U.S. patents and 8 pending U.S. patent applications, as well as foreign counterparts to many of these patents and patent applications.
The company’s product candidates, other than MM-398, would be subject to review as biological products under biologics license application (BLA) standards. MM-398 would be subject to review as a drug under new drug application (NDA) standards. MM-302 contains both drug and biological components. This combination product would be subject to review as a biological product pursuant to a BLA.
Biosimilars law: The Biologics Price Competition and Innovation Act of 2009, or BPCIA, amended the The Public Health Service Act (PHSA) to create a new licensure framework for biosimilar products, which could ultimately subject the company’s biological products to competition.
In July 2012, Merrimack Pharmaceuticals, Inc. and Cancer Treatment Centers of America, Inc. announced that they have formed a partnership to advance their long-term vision of individualized treatment where diagnosis and therapy is guided by understanding of the underlying mechanism of a patient's disease. The collaboration encompasses research on diagnostics based on a network signaling approach to analyzing patients' tumors, as well as clinical trial research.
The company was incorporated in the Commonwealth of Massachusetts in 1993 and reincorporated in the state of Delaware in 2010.
Sentiment: Strong Buy
Here is a good thread for newbies. I was from February when I was first looking into MACK. Itsawhiz is a very credible poster I have known in other biotechs and I now appreciate what he documented here as I re-establish my position in MACK. GLTA